OTOrikeda Trashi

Orikeda Trashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Orikeda Trashi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fluorescent molecular probe for in vivo and in vitro targeting and imaging of an intracellular bacterial infection

    by Shailendra Koirala, Miguel A. Gaspar, Yalini H. Wijesundara, Dong-Hao Li, Jashkaran G. Gadhvi, Ryanne N. Ehrman, Samuel A. Cornelius, Charles Mariasoosai, Thien-Quang N. Nguyen, Orikeda Trashi, et al.

    This work presents a strategy to target bacteria-infected living cells selectively. A charged zinc complex conjugated to a near-infrared reporter permeates cell membranes and binds bacterial selectively in vitro and in vivo.


  • Dually functionalized dendrimer for stimuli-responsive release of active ingredients into the skin

    by Orikeda Trashi, Neha Satish, Ikeda Trashi, Laurel M. Hagge, Yalini H. Wijesundara, Connie Hu, Fabian C. Herbert, Ronald A. Smaldone, Jeremiah J. Gassensmith


  • A Self‐Adjuvanting Large Pore 2D Covalent Organic Framework as a Vaccine Platform

    by Yalini H. Wijesundara, Niyati Arora, Ryanne N. Ehrman, Thomas Sinclair Howlett, Trevor M. Weyman, Ikeda Trashi, Orikeda Trashi, Sneha Kumari, Shashini D. Diwakara, Wendy Tang, et al.

    Vaccines are one of the greatest human achievements in public health, as they help prevent the spread of diseases, reduce illness and death rates, saving thousands of lives with few side effects. Traditional vaccine development is centered around using live attenuated or inactivated pathogens, which is expensive and has resulted in vaccine‐associated illnesses. Advancements have led to the development of safer subunit vaccines, which contain recombinant proteins isolated from pathogens. Their short half‐life and small size make most subunit vaccines less immunogenic. Here, we introduce a large pore 2D covalent organic framework (COF), PyCOFamide, as a promising solution for an effective subunit platform. Our study demonstrates that simple adsorption of a model antigen, ovalbumin (OVA), onto PyCOFamide (OVA@COF) significantly enhances humoral and cell‐mediated immune response compared to free OVA. OVA@COF exhibited heightened immune cell activation and acts as an antigen reservoir, facilitating antigen‐presenting cell trafficking to the draining lymph nodes, amplifying the humoral immune response. Additionally, the breakdown of the COF releases monomers that adjuvant the activation of immune cells vital to creating strong immunity. This platform offers a potential avenue for safer, more effective subunit vaccines.


  • A Self‐Adjuvanting Large Pore 2D Covalent Organic Framework as a Vaccine Platform

    by Yalini H. Wijesundara, Niyati Arora, Ryanne N. Ehrman, Thomas Sinclair Howlett, Trevor M. Weyman, Ikeda Trashi, Orikeda Trashi, Sneha Kumari, Shashini D. Diwakara, Wendy Tang, et al.

    Vaccines are one of the greatest human achievements in public health, as they help prevent the spread of diseases, reduce illness and death rates, saving thousands of lives with few side effects. Traditional vaccine development is centered around using live attenuated or inactivated pathogens, which is expensive and has resulted in vaccine‐associated illnesses. Advancements have led to the development of safer subunit vaccines, which contain recombinant proteins isolated from pathogens. Their short half‐life and small size make most subunit vaccines less immunogenic. Here, we introduce a large pore 2D covalent organic framework (COF), PyCOFamide, as a promising solution for an effective subunit platform. Our study demonstrates that simple adsorption of a model antigen, ovalbumin (OVA), onto PyCOFamide (OVA@COF) significantly enhances humoral and cell‐mediated immune response compared to free OVA. OVA@COF exhibited heightened immune cell activation and acts as an antigen reservoir, facilitating antigen‐presenting cell trafficking to the draining lymph nodes, amplifying the humoral immune response. Additionally, the breakdown of the COF releases monomers that adjuvant the activation of immune cells vital to creating strong immunity. This platform offers a potential avenue for safer, more effective subunit vaccines.


  • Mn and Zn‐Doped Multivariate Metal–Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection

    by Thomas S. Howlett, Sneha Kumari, Ryanne N. Ehrman, Jesse Masson, Linda Izzo, Trixie Wang, Humera Gull, Ikeda Trashi, Wendy Tang, Orikeda Trashi, et al.

    A first‐in‐class vaccine adjuvant delivery system, Mn‐ZIF, is developed by incorporating manganese (Mn) into the zinc‐containing zeolitic‐imidazolate framework‐8 (ZIF‐8). The mixed metal approach, which allowed for tunable Mn doping, is made possible by including a mild reducing agent in the reaction mixture. This approach allows up to 50% Mn, with the remaining 50% Zn within the ZIF. This multivariate approach exhibits significantly decreased cytotoxicity compared to ZIF‐8. The porous structure of Mn‐ZIF enables the co‐delivery of the STING agonist cyclic di‐adenosine monophosphate (CDA) through post‐synthetic loading, forming CDA@Mn‐ZIF. The composite demonstrated enhanced cellular uptake and synergistic activation of the cGAS‐STING pathway, producing proinflammatory cytokines and activating antigen‐presenting cells (APCs). In a preclinical Mycobacterium tuberculosis (Mtb) model, CDA@Mn‐ZIF formulates with the CysVac2 fusion protein elicited a potent antigen‐specific T‐cell response and significantly reduced the mycobacterial burden in the lungs of infected mice. These findings highlight the potential of CDA@Mn‐ZIF as a promising adjuvant for subunit vaccines, offering a novel approach to enhancing vaccine efficacy and protection against infectious diseases such as tuberculosis.


  • Enhanced Nanobubble Formation: Gold Nanoparticle Conjugation to Qβ Virus-like Particles

    by Perouza Parsamian, Yaning Liu, Chen Xie, Zhuo Chen, Peiyuan Kang, Yalini H. Wijesundara, Noora M. Al-Kharji, Ryanne Nicole Ehrman, Orikeda Trashi, Jaona Randrianalisoa, et al.

    Plasmonic gold nanostructures are a prevalent tool in modern hypersensitive analytical techniques such as photoablation, bioimaging, and biosensing. Recent studies have shown that gold nanostructures generate transient nanobubbles through localized heating and have been found in various biomedical applications. However, the current method of plasmonic nanoparticle cavitation events has several disadvantages, specifically including small metal nanostructures (≤10 nm) which lack size control, tuneability, and tissue localization by use of ultrashort pulses (ns, ps) and high-energy lasers which can result in tissue and cellular damage. This research investigates a method to immobilize sub-10 nm AuNPs (3.5 and 5 nm) onto a chemically modified thiol-rich surface of Qβ virus-like particles. These findings demonstrate that the multivalent display of sub-10 nm gold nanoparticles (AuNPs) caused a profound and disproportionate increase in photocavitation by upward of 5-7-fold and significantly lowered the laser fluency by 4-fold when compared to individual sub-10 nm AuNPs. Furthermore, computational modeling showed that the cooling time of QβAuNP scaffolds is significantly extended than that of individual AuNPs, proving greater control of laser fluency and nanobubble generation as seen in the experimental data. Ultimately, these findings showed how QβAuNP composites are more effective at nanobubble generation than current methods of plasmonic nanoparticle cavitation.